Ruxoprubart clinical trials
Also written NM8074.
How each study uses ruxoprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ruxoprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NM8074
- 9
Studies by the year they started
5 studies that test it; most in 2026 (4); 4 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
NovelMed Therapeutics (9)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test ruxoprubart.
- Aug 2027Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyPhase 2 · NovelMed Therapeutics
- Sep 2027Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase 2 · NovelMed Therapeutics
- Oct 2027Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)Phase 2 · NovelMed Therapeutics
- Nov 2027Study of NM8074 in Patients with Dermatomyositis (DM)Phase 2 · NovelMed Therapeutics
Studies
Open first, then newest update. How each study uses ruxoprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisNot yet recruitingPhase 2NovelMed TherapeuticsNCT05646563Written as NM8074
- Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingPhase 2NovelMed TherapeuticsNCT06454110Written as NM8074
- Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic MicroangiopathyNot yet recruitingPhase 2NovelMed TherapeuticsNCT05684159Written as NM8074
- Study of NM8074 in Adult C3 Glomerulopathy PatientsNot yet recruitingPhase 1/2NovelMed TherapeuticsNCT05647811Written as NM8074
- Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruitingPhase 2NovelMed TherapeuticsNCT05731050Written as NM8074
- Study of NM8074 in Patients with Dermatomyositis (DM)Not yet recruitingPhase 2NovelMed TherapeuticsNCT06887738Written as NM8074
- Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)Not yet recruitingPhase 2NovelMed TherapeuticsNCT06226662Written as NM8074
- Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyNot yet recruitingPhase 2NovelMed TherapeuticsNCT05646524Written as NM8074
- First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult VolunteersCompletedPhase 1NovelMed TherapeuticsNCT05642546Written as NM8074
Codes
What other systems call ruxoprubart · ClinicalTrials.gg INT017560
- UNII (FDA) P9NB0SOG5XRUXOPRUBARTOne source FDA
- NCI Thesaurus C199294RuxoprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P9NB0SOG5X | RUXOPRUBART | One source FDA |
| NCI Thesaurus | C199294 | Ruxoprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.